V
46.05
0.60 (1.32%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bullish | Bullish |
Biotechnology (Global) | Bullish | Bullish | |
Stock | Vericel Corporation | Bullish | Bullish |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
52 Weeks Range |
30.18 - 53.05
|
|
Price Target Range | ||
High | 54.00 (Truist Securities, 17.26%) | Buy |
Median | 53.50 (16.18%) | |
Low | 53.00 (HC Wainwright & Co., 15.09%) | Buy |
Average | 53.50 (16.18%) | |
Total | 2 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Truist Securities | 26 Mar 2024 | 54.00 (17.26%) | Buy | 49.56 |
01 Mar 2024 | 54.00 (17.26%) | Buy | 44.71 | |
HC Wainwright & Co. | 01 Mar 2024 | 53.00 (15.09%) | Buy | 44.71 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
COLANGELO DOMINICK | - | - | 0 | 0 |
Aggregate Net Quantity | 0 | |||
Aggregate Net Value ($) | 0 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | - |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
COLANGELO DOMINICK | Officer | 30 Apr 2024 | Option execute | 25,445 | - | - |
Date | Type | Details |
---|---|---|
24 Apr 2024 | Announcement | Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 |
29 Feb 2024 | Announcement | Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance |
27 Feb 2024 | Announcement | Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 |
15 Feb 2024 | Announcement | Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 |
05 Feb 2024 | Announcement | Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 |
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |